Reduced-dose craniospinal radiation and smaller volume boost for medulloblastoma patients
Trial Shows Reduced Radiation May Help Children With Medulloblastoma
This randomized phase 3 trial evaluated reduced-dose craniospinal radiation (18.00 Gy) and a smaller volume boost in children aged 3 to 7 wi…
A large clinical trial looked at whether reducing radiation doses for children with medulloblastoma can maintain safety and effectiveness.
Pleuropulmonary blastoma diagnosed after initial rhabdomyosarcoma interpretation in a 2-year-old boy
Case report shows rare lung cancer in toddler with DICER1
This case report describes a 2-year-old boy with a thoracic mass initially interpreted as embryonal rhabdomyosarcoma, later diagnosed as ple…
A toddler’s lung tumor was reclassified as a rare cancer linked to DICER1 syndrome, changing his treatment and highlighting a key diagnosis …
Phase II pilot study of hu14.18K322A plus chemotherapy in 153 children with high-risk neuroblastoma
New Antibody Boosts Survival in High-Risk Neuroblastoma
This Phase II pilot study enrolled 153 previously untreated children with high-risk neuroblastoma. The study assessed hu14.18K322A combined …
This study shows that combining a new antibody with standard chemotherapy may improve survival rates for children with high-risk neuroblasto…
Interval-compressed VDC/IE protocol feasibility and outcomes in 27 Ewing's sarcoma patients at a North African center
Compressed chemotherapy showed mixed results for Ewing's sarcoma patients in a small study.
This retrospective, single-institutional cohort study evaluated an interval-compressed VDC/IE protocol in 27 patients with Ewing's sarcoma t…
A small study found that a compressed chemotherapy regimen for Ewing's sarcoma had high toxicity and low survival rates.
Attenuated R-THP-COP regimen achieved complete response in an 85-year-old with diffuse large B-cell lymphoma
Attenuated R-THP-COP regimen shows promise for elderly diffuse large B-cell lymphoma
This case report describes an 85-year-old female patient with diffuse large B-cell lymphoma treated with an attenuated R-THP-COP regimen. Th…
An 85-year-old woman achieved complete radiological response and remained symptom-free for three years on an attenuated chemotherapy regimen…
TAC chemotherapy improves relapse-free survival in certain early breast cancer subtypes
Doctors found that certain tumor markers might help choose the best cancer treatment plan for some patients
A randomized trial compared TAC to ddAC in early breast cancer. The authors observed improved relapse-free survival in specific tumor subtyp…
This study looked at how two different drug schedules worked for people with early breast cancer. Results suggest that specific tumor featur…
Case report details treatment of ANCA-associated vasculitis with Evans syndrome and cerebral infarction in a 72-year-old woman
Treatment stabilized some symptoms but not others in a single patient case
This case report describes a 72-year-old female with ANCA-associated vasculitis, Evans syndrome, and cerebral infarction treated with cortic…
A 72-year-old woman with complex blood vessel disease saw some health markers improve while others remained poor after specific treatments.
Meta-analysis of double-expressor lymphoma prognoses and novel therapies
Double-expressor lymphoma linked to worse survival outcomes in large study
This systematic evaluation meta-analysis of 9,808 patients with diffuse large B-cell lymphoma found double-expressor lymphoma (DEL) is assoc…
A major review finds double-expressor lymphoma patients have worse survival. New drug combinations show promise for better results.
Tucidinostat plus R-CHOP improves outcomes in MYC/BCL2 double-expressor DLBCL
New drug tucidinostat improves outcomes for high-risk lymphoma patients
A phase 3 trial found adding oral tucidinostat to R-CHOP significantly improved event-free survival and complete response rates in patients …
A large trial shows adding tucidinostat to standard chemo lowers disease risk and improves survival for patients with aggressive lymphoma.
Ibrutinib plus chemo without ASCT shows survival benefit in mantle cell lymphoma
Adding stem cell transplant to ibrutinib treatment offered no extra benefit for lymphoma patients
In younger patients with mantle cell lymphoma, adding ASCT to an ibrutinib regimen did not improve outcomes but increased toxicity. Ibrutini…
Adding stem cell transplant to ibrutinib did not improve survival for younger lymphoma patients but increased side effects.
Marburg MS case shows treatment challenges and fatal outcome
A Rare MS Variant Defied Treatment Until This Switch
A 46-year-old woman with aggressive Marburg MS faced treatment-limiting toxicity and died despite multiple therapies, highlighting urgent ca…
A woman with a rare, aggressive form of multiple sclerosis tried many treatments without success, and doctors tried a new approach too late.
Meta-analysis links CYP2C19*2 polymorphism to reduced cyclophosphamide toxicity in SLE
Genetic marker may lower risk of cyclophosphamide toxicity in lupus patients
This meta-analysis of 5 observational studies found that the CYP2C19*2 genetic polymorphism is associated with a protective effect against…
A genetic variant linked to lower risk of cyclophosphamide side effects in lupus patients, though evidence remains limited by small study si…
All cyclophosphamide Articles
- Reduced-dose craniospinal radiation and smaller volume boost for medulloblastoma patients
- Pleuropulmonary blastoma diagnosed after initial rhabdomyosarcoma interpretation in a 2-year-old boy
- Interval-compressed VDC/IE protocol feasibility and outcomes in 27 Ewing's sarcoma patients at a North African center
- Phase II pilot study of hu14.18K322A plus chemotherapy in 153 children with high-risk neuroblastoma
- Attenuated R-THP-COP regimen achieved complete response in an 85-year-old with diffuse large B-cell lymphoma
- TAC chemotherapy improves relapse-free survival in certain early breast cancer subtypes
- Case report details treatment of ANCA-associated vasculitis with Evans syndrome and cerebral infarction in a 72-year-old woman
- Meta-analysis of double-expressor lymphoma prognoses and novel therapies
- Tucidinostat plus R-CHOP improves outcomes in MYC/BCL2 double-expressor DLBCL
- Ibrutinib plus chemo without ASCT shows survival benefit in mantle cell lymphoma
- Marburg MS case shows treatment challenges and fatal outcome
- UK trial reports 4-year event-free survival of 63% and overall survival of 68% in relapsed Wilms tumour patients
- Meta-analysis links CYP2C19*2 polymorphism to reduced cyclophosphamide toxicity in SLE
- Zanubrutinib associated with higher 3-year PFS versus acalabrutinib-venetoclax in treatment-naive CLL
- Systematic review of immunosuppression for SLE-associated intestinal pseudo-obstruction
- RCD chemotherapy in Waldenström macroglobulinemia with AL amyloidosis led to rapid progression and death
- Nailfold videocapillaroscopy patterns associate with interstitial lung disease and skin fibrosis in systemic sclerosis patients
- Mitoxantrone liposome plus CMOP shows high response rates in untreated peripheral T-cell lymphoma patients
- Therapeutic plasma exchange in pediatric autoimmune diffuse alveolar hemorrhage shows 5 of 6 survival
- Network meta-analysis of adjuvant chemotherapy regimens for early-stage breast cancer identifies optimal dosing sequences and safety profiles
- Phase 2 trial compares Inotuzumab Ozogamicin plus R-CVP for DLBCL patients unfit for anthracycline
- R-CVP after radiotherapy improves progression-free survival in early-stage follicular lymphoma
- Phase I/II trial tests IMRT with chemotherapy before transplant for relapsed/refractory ALL/AML
- Phase II trial of cyclophosphamide, paclitaxel, trastuzumab in stage I-II HER2+ breast cancer completes with 20 patients